Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Verichem updates data reduction software

May 2024—Verichem Laboratories has upgraded its Web-based, CLIA-compliant data reduction and test reporting software. The new version allows customers to save reports on the company’s server for future editing and edit previous submissions for up to three days after the initial submission. Previous submissions are autosaved so users can edit data without rekeying or reentering any other component information. The software is available to customers at no cost.

Newcomer Supply to distribute HistoCyte cell line controls

May 2024—Newcomer Supply announced it is distributing HistoCyte Laboratories cell line controls for research use only. HistoCyte uses proprietary methods to process cell lines into tissue-like controls. The products are standardized, developed, and manufactured to provide consistent morphology and staining results throughout the FFPE block. Cell line controls are available as either precut slides or in cell microarray blocks.

Bruker to acquire NanoString for $392.6 million

May 2025—NanoString Technologies announced that substantially all of its assets will be acquired by Bruker Corp. for approximately $392.6 million in cash consideration, plus the assumption of certain liabilities. The transaction was agreed to under a court-supervised Chapter 11 sale process and is expected to close in early May.

FDA grants de novo classification for plasma cell enrichment kit

May 2024—Stemcell Technologies announced that the FDA has granted de novo classification for its immunomagnetic plasma cell enrichment kit. The EasySep Human Bone Marrow CD138 Positive Selection kit, for in vitro diagnostic applications, is intended to enrich CD138 positive plasma cells from bone marrow samples collected from patients with multiple myeloma, as part of a preanalytical workflow. Commercial launch of the kit is planned in the European Union, Canada, the United Kingdom, and the United States.

FDA approves test to screen for malaria in blood donors

April 2024—Roche announced FDA approval of the Cobas Malaria test, a qualitative in vitro nucleic acid screening test for the direct detection of Plasmodium RNA and DNA in whole blood samples from individual human donors. The test can be performed with other routine blood donor screening tests and is designed for use on the Cobas 6800/8800 systems in the United States.

FDA clears Diasorin Liaison Plex system

April 2024—Diasorin announced FDA 510(k) clearance for its Liaison Plex platform and Flex respiratory assay. The fully automated, sample-to-answer system uses room-temperature–stable consumables and has a hands-on time of two minutes per sample. Results are available in less than two hours. Diasorin says Flex testing allows users to generate and pay for a subset of specific results based on a patient’s clinical picture.

Siemens offers anti-müllerian hormone assay

April 2024—Siemens Healthineers now offers the Anti-Müllerian Hormone assay to evaluate ovarian reserve. The assay runs on the Atellica IM analyzer and Advia Centaur immunoassay systems from serum and plasma samples. Results are available in about 28 minutes.

FDA clears Sebia free light chain assays

April 2024—Sebia announced it has received FDA 510(k) clearance for its free light chain kappa and lambda assays, intended to aid in diagnosing and monitoring patients who have multiple myeloma and immunoglobulin light chain amyloidosis. The assays quantify kappa or lambda free light chains in human serum using an enzyme-linked immunosorbent assay procedure. The kits are for in vitro diagnostic use only.

StatLab acquires Poly Scientific R&D

April 2024—StatLab Medical Products announced the acquisition of Poly Scientific R&D, a manufacturer and supplier of pathology stains, reagents, and paraffin for anatomic pathology laboratories. The acquisition includes Histology Control Systems, a division of Poly Scientific that manufactures and supplies tissue control slides.

Bio-Rad launches QC online learning center

April 2024—Bio-Rad Laboratories has launched its online Quality Controls Learning Center, a free resource designed to provide laboratories with the educational resources needed to maintain quality control patient test results. The site provides a library of articles and best practices on quality control process and design, laboratory management, quality control data management, quality control troubleshooting and solutions, and the benefits of independent quality control.

MARKETPLACE

TRENDING